Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10ng/ml

Creative Commons License

Kaygisiz O., UĞURLU Ö., Koşan M., Inal G., Öztürk B., Çetinkaya M.

Prostate Cancer and Prostatic Diseases, cilt.9, sa.3, ss.235-238, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 9 Sayı: 3
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1038/sj.pcan.4500885
  • Dergi Adı: Prostate Cancer and Prostatic Diseases
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.235-238
  • Anahtar Kelimeler: prostate inflammation, prostate-specific antigen, antibacterial therapy, prostate biopsy, CATEGORY-IV PROSTATITIS, SERUM PSA, ANTIGEN, MEN, HYPERPLASIA, PREVALENCE, BACTERIAL, CANCER, VOLUME
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

We investigated the effect of prostatic inflammation on prostate-specific antigen (PSA) and per cent-free PSA levels changing after antibacterial therapy. We evaluated 48 patients whose PSA levels were between 4 and 10ng/ml, without any suspicious findings on digital rectal examination, with no infection findings in urine analysis. Prostatic inflammation was assessed with prostatic massage. All the patients were given antibiotic therapy for 3 weeks. Patients were re-evaluated 3 weeks after antibacterial therapy with PSA (free/total) and urinalysis. Ten core biopsies were taken with transrectal ultrasound. No differences were found in terms of age, pre- and post-treatment PSA, and PSA varying between patients with and without inflammation in the prostatic massage. In 18 patients, PSA decreased below 4ng/ml. Prostate cancer was found in 10.8% of the patients with PSA between 4 and 10ng/ml and none of the patients with PSA values below 4ng/ml. We suggest an antibiotic therapy for 3 weeks without regarding inflammation findings when PSA is in the gray zone, for biopsy decision. © 2006 Nature Publishing Group All rights reserved.